

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior listings of claims in the application:

LISTING OF CLAIMS:

1-54. (Canceled).

55. (New) A nucleic acid fragment that encodes a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO: 2, residues 17-677.

56. (New) The nucleic acid fragment according to claim 55, which is a DNA fragment.

57. (New) A vector carrying the nucleic acid fragment according to claim 56.

58. (New) The vector according to claim 57, which is capable of autonomous replication.

59. (New) The vector according to claim 58 being selected from the group consisting of a plasmid, a phage, a cosmid, and a virus.

60. (New) The vector according to claim 57, which is an expression vector.

61. (New) The vector according to claim 60, comprising in the 5' → 3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment, a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the encoded polypeptide, and the nucleic acid fragment.

62. (New) A transformed host cell carrying the vector of claim 57.

63. (New) A transformed host cell carrying the vector of claim 60.

64. (New) A stable cell line which carries the vector according to claim 60.

65. (New) An immunogenic composition for immunizing against HER-2

protein in a human comprising the vector according to claim 60 in admixture with a pharmaceutically acceptable carrier or vehicle and optionally an adjuvant.

66. (New) A nucleic acid fragment that encodes a polypeptide that consists of the amino acid sequence set forth in SEQ ID NO: 2, residues 17-677.